RAGE Biotech’s Post

🔬 Cell Spotlight - October ✨ Introducing our Chronic Obstructive Pulmonary Disease (COPD) research models: • Immortalized Human Small Airway Epithelial Cells (COPD) - SV40T (SKU T0399) 🔗 https://buff.ly/4gUBPyG • Immortalized COPD Bronchial/Tracheal Epithelial Cells - SV40T (SKU T0406). 🔗 https://buff.ly/3U2q6V3 These cell lines are engineered using the SV40T antigen, ensuring robust proliferation and longevity, making them ideal for long-term studies. These cell lines provide a reliable and reproducible platform for exploring the pathophysiology of COPD, facilitating drug discovery, and therapeutic development. Empower your research with these advanced cell lines, designed to mimic the unique characteristics of COPD-affected airway epithelium, and accelerate your journey towards breakthroughs in respiratory medicine. #Cell #CellSpotlight #CellLine #ImmortalizedCells #Product

🌍 𝗥𝗮𝗶𝘀𝗶𝗻𝗴 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗳𝗼𝗿 𝗔𝗟 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀 𝗗𝗮𝘆 - 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟲, 𝟮𝟬𝟮𝟰 🌍 AL amyloidosis is a rare but serious condition that can impact the heart, kidneys, nervous system, and more. Awareness and early detection are key to improving outcomes for those affected. Today, we stand in solidarity with patients, caregivers, and the medical community to bring greater attention to this disease. At 𝗦𝗶𝗲𝗺𝗲𝗻𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗶𝗻𝗲𝗲𝗿𝘀, we’re dedicated to providing laboratories with advanced tools to support both the diagnosis and monitoring of AL amyloidosis. Our 𝗡 𝗟𝗮𝘁𝗲𝘅 𝗙𝗟𝗖 Kit offers sensitive detection of free light chains (FLC) in the blood—an essential marker in identifying and tracking AL amyloidosis. This precise measurement helps clinicians monitor disease progression and assess treatment response, providing valuable insights every step of the way. In addition to the N Latex FLC Kit, Siemens Healthineers offers other key assays to further aid in diagnosis: • Serum Immunoglobulins (IgG, IgA, IgM) to identify monoclonal proteins. • Complement Proteins (C3, C4) for immune system evaluation. • Serum Amyloid A (SAA), an acute-phase reactant for monitoring disease activity. Join us in spreading awareness on 𝗔𝗟 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀 𝗗𝗮𝘆, and learn more about the Amyloidosis Alliance: https://lnkd.in/eaDN_AJj For additional information on our full range of assays, visit our Plasma Protein landing page: https://lnkd.in/efNf3wYv Together, we can make a difference. #ALAmyloidosisDay #SiemensHealthineers #NLatexFLC #FLC #AmyloidosisAwareness

Exciting Advances in Rheumatic Disease Treatment! Recent studies are paving the way for a future where reliance on traditional glucocorticoid (GC) therapies could be significantly reduced, minimizing their notorious side effects. 🔬 Innovative Research: 11β-HSD1 Inhibitors like SPI-62 and AZD4017 have shown promising results in reducing GC side effects such as insulin resistance and bone health issues. Sarilumab and Tocilizumab, IL-6 receptor blockers, have demonstrated efficacy in allowing faster and more controlled GC tapering with fewer relapses in conditions like PMR and GCA. 🩺 These emerging treatments not only enhance disease management but also improve patient quality of life by reducing the adverse effects associated with long-term steroid use. 🚀 As these clinical trials progress, we are hopeful for a future with more personalized and safer therapeutic options for rheumatic diseases. Stay tuned for more updates on these groundbreaking advancements! 💡 #Rheumatology #MedicalResearch #PatientCare #InnovativeMedicine #HealthcareTransformation #Glucocorticoids #SteroidSparing #ClinicalTrials

This study identifies a greater presence of airway innate lymphoid cells type 2 (ILC2s) with TSLP receptors and IL-5 expression in eosinophilic COPD (eCOPD) patients compared to non-eosinophilic COPD and healthy smokers. Additionally, ILC2 levels in sputum were positively correlated with sputum eosinophilia. These findings suggest a role for epithelial alarmin-activated ILC2s in driving airway eosinophilic inflammation in COPD, potentially offering new insights into targeted therapies for eCOPD. Free access at https://lnkd.in/dwDTt4HZ. #COPD #eosinophilicCOPD #airwayinflammation #ILC2 #PulmonaryResearch

Today, on World Sickle Cell Day, we stand in solidarity with individuals and families affected by sickle cell disease, reaffirming our commitment to advancing diagnostics and improving patient care. At Diazyme Laboratories, we understand the critical importance of early detection and monitoring in managing this complex condition. Studies show the crucial role Ferritin Assays play in the diagnosis and management of sickle cell disease by providing accurate and reliable measurements of ferritin levels. Elevated Ferritin levels are often indicative of increased iron levels in the body, a common complication in sickle cell disease that can lead to serious health issues. On this meaningful day, we recognize the resilience of those living with sickle cell disease and the tireless efforts of healthcare professionals dedicated to their care. Through our innovative diagnostic solutions, we strive to empower healthcare providers with the tools they need to improve patient outcomes and enhance quality of life. Together, let's raise awareness, foster compassion, and advocate for better access to care for individuals and communities affected by sickle cell disease. Contact a rep to learn more: https://bit.ly/2BuMrVS **Diazyme’s Ferritin Assay is FDA approved he quantitative determination of ferritin in human serum, K2EDTA plasma, and lithium heparin plasma on Hitachi 917 analyzer. For in vitro diagnostic use only. ** #WorldSickleCellDay #SickleCellAwareness #DiazymeLaboratories #FerritinAssay #Healthcare #Diagnostics #Innovation #PatientCare #CommunitySupport

Our goal is to make therapies accessible for the >90% of people with a #raredisease who lack them. Join us on October 1st for the 1st Annual Respiratory Rare Disease Accelerator Day at The Francis Crick Institute. 👉 https://lnkd.in/ezN7RDuz Globally, more than 300 million people are living with #rarediseases, of which one in 20 are related to #respiratory conditions. While rare on their own, collectively they represent significant social and economic costs. Given more than 90% of rare diseases lack an FDA-approved treatment, rare respiratory diseases represent a phenomenal growth opportunity. With our new LifeArc Centre for Rare Respiratory Diseases, we embody this bold ambition to improve diagnosis and care for patients living with rare respiratory disease and foster innovation for much-needed treatments and cures. Leading with three disease exemplars, we aim to de-risk translation from discovery through to clinical trials. We showcase primary ciliary dyskinesia (PCD), which affects 1:7000 births, which impairs mucociliary clearance leading to decline in lung function similar to #cysticfibrosis (CF). Unlike #CF, no approved treatments exist for PCD, despite a similar market size and unmet significant need. Together, we aim to change this.   This event will have wider applicability across rare disease and #personalisedmedicine showing how we can connect all the dots to market. With support from Weatherden, LifeArc, AXON and Pinsent Masons #Raredisease #CysticFibrosys #PCDResearch #genetherapy #respiratorymedicine #translationalmedicine #CRISPR #genomics #MolecularDiagnosis #bronchiectastis

A new clinical resources web page for general practice has been set up on the PCB website. The page bring together information and links to a number of Greater Manchester (GM) specific clinical guides and pathways covering some of the most common conditions treated in general practice. These include: antibiotics, asthma, cancer, COPD, delirium, headaches, hypertension, lipid management and menopause. The clinical guidance has been produced by trusted NHS partners, including Greater Manchester Medicines Management Group (GMMMG), GatewayC and Health Innovation Manchester (HInM). Access the page on the PCB website: https://lnkd.in/eJGNHMAD #GMPrimaryCare #GeneralPractice #ClinicalGuidance

World Diabetes Day: A Step Closer to a Cure for Type 1 Diabetes On this World Diabetes Day, we are proud to share the latest update from our Diabetes Moonshot—a groundbreaking initiative focused on finding regenerative medicine solutions for type 1 diabetes. Together with passionate professionals and innovators, we are working toward a future where a cure is within reach. Last month we announced the latest breakthrough—a study published in Cell, revealing that a patient with type 1 diabetes was able to produce her own insulin using stem cells derived from her own body: https://lnkd.in/e2xSP35N At RegMed XB, we are proud to collaborate with Eelco de Koning, Professor of Diabetology from Leiden University Medical Center, who provided valuable insights into this innovative study. His expertise emphasizes the potential of stem cell-based therapies to revolutionize diabetes treatment. This aligns with the goals of our Diabetes Moonshot, which aims to create new, insulin-producing cells for individuals with type 1 diabetes. Thanks to the health foundations: Diabetes Fonds and Stichting DON (Diabetes Onderzoek Nederland) for supporting this moonshot. Together, we can make a difference. 💙 World Diabetes Day #WorldDiabetesDay #Type1Diabetes #DiabetesMoonshot #StemCells #DiabetesResearch #Innovation #RegenerativeMedicine #HopeForACure #HealthHolland #DiabetesFonds #RegMedXB #Innovation #TranslationalResearch Cc: Health~Holland International

News from First Report Managed Care: Our comprehensive idiopathic pulmonary fibrosis (IPF) white paper discusses the significance of early intervention and showcases novel therapies in development that may make a profound impact on IPF management in the future.    Read more! https://lnkd.in/eUhvapwD

Chronic Kidney Disease (#CKD) remains a significant challenge in healthcare, affecting an estimated 850 million people and ranking as the seventh leading cause of mortality worldwide. Providing reliable, up-to-date data to clinical researchers is a critical step toward developing a deeper understanding of disease diagnosis, progression, complications, and treatment. Briya's Dynamic Dataset on CKD is an invaluable resource for clinical research projects, offering live, #RealWorldData sourced from a network of hospitals. Explore our pre-curated datasets or request a customized one tailored to your needs. https://lnkd.in/dceeDezu #RealWorldEvidence